Capital Fund Management (CFM)
NKTR icon

Capital Fund Management (CFM)’s Nektar Therapeutics NKTR Stock Holding History

Capital Fund Management (CFM)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,113
Closed -$1.02M – 2103
2018
Q3 		$1.02M Sell
1,113
-234
-17% -$200K 0.01% 1369
2018
Q2 		$986K Buy
1,347
+1,014
+305% +$1.17M 0.01% 1340
2018
Q1 		$531K Buy
+333
New +$429K ﹤0.01% 1442

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Fund Management (CFM)'s NKTR Position: Q3 2022 in Review

Capital Fund Management (CFM) sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 13,756 shares — an estimated $784K sold.

Capital Fund Management (CFM) first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $43.1M in Q3 2018. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Capital Fund Management (CFM) reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 13,756 Nektar Therapeutics shares in Q3 2022, an estimated $784K.
  • Capital Fund Management (CFM) first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
  • Capital Fund Management (CFM)'s Nektar Therapeutics position peaked at $43.1M in Q3 2018.
  • 230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2022, filed 14 Nov 2022.